HRP20020787B1 - Method of treatment using ligand-immunogen conjugates - Google Patents

Method of treatment using ligand-immunogen conjugates

Info

Publication number
HRP20020787B1
HRP20020787B1 HRP20020787AA HRP20020787A HRP20020787B1 HR P20020787 B1 HRP20020787 B1 HR P20020787B1 HR P20020787A A HRP20020787A A HR P20020787AA HR P20020787 A HRP20020787 A HR P20020787A HR P20020787 B1 HRP20020787 B1 HR P20020787B1
Authority
HR
Croatia
Prior art keywords
ligand
treatment
compound
immune response
cells
Prior art date
Application number
HRP20020787AA
Other languages
English (en)
Croatian (hr)
Inventor
Stewart Low Philip
Lu Yingjuan
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Publication of HRP20020787A2 publication Critical patent/HRP20020787A2/xx
Publication of HRP20020787B1 publication Critical patent/HRP20020787B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
HRP20020787AA 2000-03-31 2002-09-30 Method of treatment using ligand-immunogen conjugates HRP20020787B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19394400P 2000-03-31 2000-03-31
US25584600P 2000-12-15 2000-12-15
PCT/US2001/010254 WO2001074382A1 (en) 2000-03-31 2001-03-30 Method of treatment using ligand-immunogen conjugates

Publications (2)

Publication Number Publication Date
HRP20020787A2 HRP20020787A2 (en) 2004-02-29
HRP20020787B1 true HRP20020787B1 (en) 2012-06-30

Family

ID=26889531

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20020787AA HRP20020787B1 (en) 2000-03-31 2002-09-30 Method of treatment using ligand-immunogen conjugates

Country Status (20)

Country Link
US (2) US7033594B2 (xx)
EP (1) EP1267918A4 (xx)
JP (2) JP5059271B2 (xx)
KR (1) KR100863632B1 (xx)
CN (2) CN1441676B (xx)
AU (2) AU5697001A (xx)
BR (1) BR0109704A (xx)
CA (1) CA2405299C (xx)
CZ (1) CZ304942B6 (xx)
DZ (1) DZ3332A1 (xx)
EA (1) EA005823B1 (xx)
HR (1) HRP20020787B1 (xx)
HU (1) HUP0300421A2 (xx)
IL (2) IL151927A0 (xx)
MX (1) MXPA02009454A (xx)
NO (1) NO332160B1 (xx)
NZ (1) NZ521898A (xx)
PL (1) PL211872B1 (xx)
SK (1) SK288201B6 (xx)
WO (1) WO2001074382A1 (xx)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927203B1 (en) 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
US7192698B1 (en) 1999-08-17 2007-03-20 Purdue Research Foundation EphA2 as a diagnostic target for metastatic cancer
CA2328356A1 (en) * 1999-12-22 2001-06-22 Itty Atcravi Recreational vehicles
US7645743B2 (en) * 1999-12-22 2010-01-12 Altermune, Llc Chemically programmable immunity
AU5697001A (en) 2000-03-31 2001-10-15 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
US7101976B1 (en) 2000-09-12 2006-09-05 Purdue Research Foundation EphA2 monoclonal antibodies and methods of making and using same
ATE427948T1 (de) * 2001-04-24 2009-04-15 Purdue Research Foundation Folat-mimetika und deren folatrezeptorbindende konjugate
PL367102A1 (en) 2001-05-02 2005-02-21 Purdue Research Foundation Treatment and diagnosis of macrophage mediated disease
ATE451935T1 (de) * 2001-09-28 2010-01-15 Purdue Research Foundation Behandlungsverfahren mit liganden- immunogenkonjugaten
WO2003034995A2 (en) * 2001-10-22 2003-05-01 The Scripps Research Institute Integrin targeting compounds
US8043602B2 (en) * 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US8043603B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
AR039429A1 (es) * 2002-04-19 2005-02-16 Endocyte Inc Metodo para aumentar la eliminacion especifica mediada por la respuesta inmune endogena de la poblacion de celulas patogenicas en un animal huesped inmunizado previamente, composicion y combinacion que comprenden un auxiliar th1 y un conjugado hapten-portador de utilidad en el mismo.
ATE530577T1 (de) * 2002-05-10 2011-11-15 Purdue Research Foundation Epha2 agonistische monoklonale antikörper und deren anwendungsverfahren
ES2373715T3 (es) * 2002-05-10 2012-02-08 Medimmune, Llc Anticuerpos monoclonales frente a epha2 y procedimientos de uso de los mismos.
US20050152899A1 (en) * 2002-05-10 2005-07-14 Kinch Michael S. EphA2 agonistic monoclonal antibodies and methods of use thereof
CA2484640C (en) * 2002-05-15 2012-01-17 Endocyte, Inc. Vitamin-mitomycin conjugates
WO2004069159A2 (en) * 2003-01-27 2004-08-19 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
EP2230249A3 (en) 2003-02-06 2010-12-22 ChronTech Pharma AB Antigen/antibody or ligand/receptor glycosylated specificity exchangers
AU2004229543A1 (en) * 2003-04-11 2004-10-28 Medimmune, Llc EphA2 and non-neoplastic hyperproliferative cell disorders
EP1622646B1 (en) * 2003-05-06 2012-08-08 Purdue Research Foundation Treatment of lupus targeting the macrophages or the folate receptor
ES2317010T3 (es) * 2003-05-30 2009-04-16 Purdue Research Foundation Metodo de diagnostico de la arterosclerosis.
US7601511B2 (en) * 2003-11-12 2009-10-13 University Of Georgia Research Foundation, Inc. Biotin-facilitated transport in gram negative bacteria
US7785875B2 (en) 2004-07-03 2010-08-31 Mogam Biotechnology Research Institute Polynucleotide encoding HCV epitopes which can bind to various HLA supertypes, immunogenic composition comprising same and method of inducing an HCV-specific immune response using same
KR100790646B1 (ko) * 2004-07-03 2008-01-02 재단법인 목암생명공학연구소 세포매개 면역반응을 효과적으로 유도하는 ｈｃｖ수퍼타입 에피토프, 그를 코딩하는 올리고뉴클레오타이드및 그의 용도
WO2006012527A1 (en) 2004-07-23 2006-02-02 Endocyte, Inc. Bivalent linkers and conjugates thereof
RU2007128036A (ru) * 2004-12-23 2009-01-27 Пердью Рисерч Фаундейшн (Us) Способ получения изображения позитронно-эмиссионной томографией
JP5289935B2 (ja) * 2005-03-16 2013-09-11 エンドサイト，インコーポレイテッド プテロイン酸およびその結合体の合成と精製
CN101203759A (zh) 2005-03-30 2008-06-18 普渡研究基金会 使用细胞叶酸维生素受体定量法而用于癌症预后的方法
WO2007006041A2 (en) 2005-07-05 2007-01-11 Purdue Research Foundation Imaging and therapeutic method using monocytes
US20080280937A1 (en) * 2005-08-19 2008-11-13 Christopher Paul Leamon Ligand Conjugates of Vinca Alkaloids, Analogs, and Derivatives
ES2468240T3 (es) * 2005-08-19 2014-06-16 Endocyte, Inc. Conjugados de ligando de múltiples fármacos
US8795633B2 (en) 2005-09-23 2014-08-05 Purdue Research Foundation Multiphoton in vivo flow cytometry method and device
US8357671B2 (en) 2005-11-10 2013-01-22 James Paulson High affinity Siglec ligands
WO2007092299A2 (en) 2006-02-03 2007-08-16 Purdue Research Foundation Targeted conjugates and radiation
WO2007139815A2 (en) * 2006-05-23 2007-12-06 Purdue Research Foundation Imaging and therapeutic method using progenitor cells
US8486412B2 (en) 2006-06-01 2013-07-16 Mayo Foundation For Medical Education And Research Immunity to folate receptors
EP2087337A4 (en) 2006-11-03 2010-09-08 Purdue Research Foundation METHOD AND DEVICE FOR EX-VIVO FLOW CYTOMETRY
AU2008213702B2 (en) 2007-02-07 2014-04-24 Purdue Research Foundation Positron emission tomography imaging method
WO2008101231A2 (en) 2007-02-16 2008-08-21 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
CN101678124A (zh) * 2007-03-14 2010-03-24 恩多塞特公司 结合配体连接的微管溶素递药缀合物
EP2164525A2 (en) * 2007-05-25 2010-03-24 Purdue Research Foundation Method of imaging localized infections
EP3569251A1 (en) 2007-06-25 2019-11-20 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
EP3656403B1 (en) 2007-08-17 2022-05-11 Purdue Research Foundation Preparation process of psma binding ligand-linker conjugates
CA2698146C (en) 2007-08-30 2016-12-20 Daiichi Sankyo Company, Limited Anti-epha2 antibody
CA2703491C (en) 2007-10-25 2017-06-13 Endocyte, Inc. Tubulysins and processes for preparing
JP5554713B2 (ja) * 2007-11-15 2014-07-23 エンドサイト，インク． 接合体を投与する方法
HUE025618T2 (en) * 2008-05-13 2016-04-28 Univ Yale Kimer small molecules to select antibodies against cancer cells
US8852630B2 (en) 2008-05-13 2014-10-07 Yale University Chimeric small molecules for the recruitment of antibodies to cancer cells
CA2760774A1 (en) * 2009-05-05 2010-11-11 Altermune Technologies, Llc Chemically programmable immunity
KR101580713B1 (ko) 2010-02-24 2015-12-29 이뮤노젠 아이엔씨 엽산염 수용체 1 항체와 면역접합체 및 이들의 용도
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
MX2012013100A (es) 2010-05-18 2013-01-22 Cerulean Pharma Inc Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades.
UA125636C2 (uk) 2011-04-01 2022-05-11 Іммуноджен, Інк. Способи ідентифікації раку, який може реагувати на анти-folr1 антитіло або анти-folr1 імунокон'югат
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
EP2822386B1 (en) 2012-02-29 2021-05-05 Purdue Research Foundation Folate receptor alpha binding ligands
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
KR20200079565A (ko) 2012-08-31 2020-07-03 이뮤노젠 아이엔씨 엽산 수용체 1의 검출을 위한 진단성 검정 및 키트
AU2013331440A1 (en) 2012-10-16 2015-04-30 Endocyte, Inc. Drug delivery conjugates containing unnatural amino acids and methods for using
JP6892218B2 (ja) 2012-11-15 2021-06-23 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． 薬物送達結合体およびｐｓｍａ発現細胞によって引き起こされる疾患の治療方法
AU2013383382B2 (en) 2013-03-15 2017-02-23 Purdue Research Foundation Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
WO2015031815A2 (en) 2013-08-30 2015-03-05 Immunogen, Inc. Antibodies and assays for detection of folate receptor 1
GEP20237496B (en) 2013-10-18 2023-04-10 Deutsches Krebsforsch Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
GB201411150D0 (en) * 2014-06-23 2014-08-06 Altermune Technologies Llc Novel aptamers and therapeutic uses thereof
KR20170051462A (ko) * 2014-08-28 2017-05-11 아카데미슈 지켄후이스 라이덴 Ｃｄ９４／ｎｋｇ２ａ 및／또는 ｃｄ９４／ｎｋｇ２ｂ 항체, 백신 조합물
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
IL257531B2 (en) 2015-09-17 2023-04-01 Immunogen Inc Medicinal compositions containing anti-folr1 immunoconjugates
US20180067121A1 (en) * 2016-09-06 2018-03-08 Nanoco Technologies Ltd. Exosome-conjugated quantum dot nanoparticles and methods of detecting exosomes and cancer using same
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11649288B2 (en) 2017-02-07 2023-05-16 Seattle Children's Hospital Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
WO2018160622A1 (en) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions and methods for car t cell therapy
JP6990522B2 (ja) * 2017-04-11 2022-02-03 シスメックス株式会社 免疫細胞の免疫刺激応答性を測定する方法、免疫細胞における免疫シナプスの形成能を判定する方法及び細胞分析装置
CN108051581A (zh) * 2017-12-18 2018-05-18 河北中医学院 非共价键连接法半抗原---载体免疫原的制备
CN112292138A (zh) 2018-01-22 2021-01-29 西雅图儿童医院（Dba西雅图儿童研究所） Car t细胞的使用方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688488A (en) * 1989-04-03 1997-11-18 Purdue Research Foundation Composition and method for tumor imaging

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2816110A (en) * 1956-11-23 1957-12-10 Merck & Co Inc Methods for the production of substituted pteridines
US4314988A (en) 1979-10-31 1982-02-09 Baker Instruments Corp. Folic acid derivatives and process for preparation
US4713249A (en) * 1981-11-12 1987-12-15 Schroeder Ulf Crystallized carbohydrate matrix for biologically active substances, a process of preparing said matrix, and the use thereof
US4659655A (en) * 1981-11-25 1987-04-21 Bio-Response, Inc. Method for isolating product-producing cells
US5140104A (en) * 1982-03-09 1992-08-18 Cytogen Corporation Amine derivatives of folic acid analogs
ES8407097A1 (es) 1982-05-12 1984-08-16 Harvard College Un procedimiento para obtener una proteina hibrida.
NL8401226A (nl) 1984-04-16 1985-11-18 Univ Utrecht Farmaceutisch produkt met anti-tumorwerking; gebruik van een farmaceutisch produkt of van farmaceutische samenstellingen in een anti-tumortherapie.
ATE74622T1 (de) 1984-10-31 1992-04-15 Massachusetts Inst Technology Verfahren zum sensibilisieren einer zielzelle zum lysen durch cytotoxische t-lymphkoerperchen.
US5266333A (en) * 1985-03-06 1993-11-30 American Cyanamid Company Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration of growth hormone
US4681760A (en) 1985-04-17 1987-07-21 The Board Of Trustees Of The Leland Stanford Junior University Method of conferring immunotolerance to a specific antigen
CA1282069C (en) * 1985-09-12 1991-03-26 Damon L. Meyer Antibody complexes of hapten-modified diagnostic or therapeutic agents
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
NZ217821A (en) 1985-10-10 1989-07-27 Biotech Australia Pty Ltd Oral delivery system; complex of active agent and vitamin b12 or analogue thereof
US5117022A (en) * 1985-10-18 1992-05-26 The Board Of Regents, The University Of Texas System Hydrophobic cis-platinum complexes efficiently incorporated into liposomes
JPS6479125A (en) 1986-08-13 1989-03-24 Takeda Chemical Industries Ltd Antitumor agent
GB8626413D0 (en) 1986-11-05 1986-12-03 Gilliland L K Antibodies
US5888512A (en) 1987-01-30 1999-03-30 Board Of Trustees Of The Leland Stanford Junior University Lymphocyte activity regulation by HLA peptides
US4971792A (en) 1987-03-27 1990-11-20 The Wistar Institute Monoclonal antibodies against glycolipid antigens
US5583112A (en) 1987-05-29 1996-12-10 Cambridge Biotech Corporation Saponin-antigen conjugates and the use thereof
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4946945A (en) 1987-06-23 1990-08-07 Allergy Immuno Technologies, Inc. Immunotherapy agents for treatment of IgE mediated allergies
DE3880766D1 (de) 1987-09-02 1993-06-09 Ciba Geigy Ag Konjugate von interferon alpha mit immunglobulinen.
DK8189A (da) 1988-01-12 1989-07-13 Bunge Australia Antigen-antistof-konjugater, deres fremstilling og anvendelse
GB8803365D0 (en) 1988-02-13 1988-03-16 Ciba Geigy Ag Antiviral combination
EP0334300A1 (en) 1988-03-21 1989-09-27 Neorx Corporation The use of monoclonal antibodies and conjugates thereof as signals to direct sensitized effector cells to tumor sites
DE3825615A1 (de) 1988-07-28 1990-02-01 Behringwerke Ag Antigenkonstrukte von "major histocompatibility complex" klasse i antigenen mit spezifischen traegermolekuelen, ihre herstellung und verwendung
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
DE68926380T2 (de) 1988-11-14 1996-09-12 Kanegafuchi Chemical Ind Sphärische Vinylchloridharzgranulate und Verfahren zu ihrer Herstellung
JPH02169521A (ja) 1988-12-22 1990-06-29 Ajinomoto Co Inc 自己免疫疾患治療剤
CA2047244C (en) 1989-02-24 2002-09-17 Zanetti Maurizio Genetically engineered immunoglobulins
US5075287A (en) 1989-03-03 1991-12-24 Nisshin Oil Mills, Inc. Muramyl peptide derivatives and immunoregulating compositions containing them
GB8907310D0 (en) 1989-03-31 1989-05-17 Medical Res Council Heteroconjugates
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5217881A (en) 1989-04-25 1993-06-08 Immunex Corporation Hyperglycosylated cytokine conjugates
JPH04501808A (ja) 1989-07-06 1992-04-02 セラジェン・インコーポレーテッド ハイブリッド分子
JPH04506662A (ja) 1989-07-14 1992-11-19 アメリカン・サイアナミド・カンパニー 接合体ワクチンのためのサイトカイニンおよびホルモンのキヤリヤー
JP2807831B2 (ja) 1989-07-18 1998-10-08 国際試薬株式会社 免疫学的測定法
JPH0686375B2 (ja) 1989-09-25 1994-11-02 大塚製薬株式会社 リポソーム製剤
JPH03206886A (ja) 1989-11-13 1991-09-10 Green Cross Corp:The ヒト腫瘍細胞抗原に対し特異性を持つマウス―ヒトキメラａ１０抗体
ES2171392T3 (es) 1990-08-29 2002-09-16 Ct Hospitalier Regional De Nan Poliligandos de proteina unidos a un nucleo de proteina estable.
JP3105629B2 (ja) 1991-04-23 2000-11-06 サングスタット メディカル コーポレイション 特異的結合ペアのメンバーの細胞活性調節接合体
IT1244983B (it) 1991-04-29 1994-09-13 Raggio Italgene Spa Procedimento per rivelare sequenze di acidi nucleici e kit per la sua utilizzazione.
JP3173814B2 (ja) 1991-05-30 2001-06-04 株式会社タムラ製作所 フラックス塗布方法
US6335434B1 (en) * 1998-06-16 2002-01-01 Isis Pharmaceuticals, Inc., Nucleosidic and non-nucleosidic folate conjugates
US5159079A (en) * 1991-12-20 1992-10-27 Eli Lilly And Company 2-piperidones as intermediates for 5-deaza-10-oxo- and 5-deaza-10-thio-5,6,7,8-tetrahydrofolic acids
US5650398A (en) 1992-07-02 1997-07-22 Cambridge Biotech Corporation Drug delivery enhancement via modified saponins
US5273965A (en) 1992-07-02 1993-12-28 Cambridge Biotech Corporation Methods for enhancing drug delivery with modified saponins
DK0609606T3 (xx) 1992-10-01 1997-03-17 Wellcome Found
DE4238416A1 (de) 1992-11-13 1994-05-19 Max Planck Gesellschaft Bestimmung von Peptidmotiven auf MHC-Molekülen
US5747024A (en) 1993-03-08 1998-05-05 Immunex Corporation Vaccine adjuvant comprising interleukin-15
US5932208A (en) 1993-03-19 1999-08-03 Vacsyn S.A. Compositions and methods for the use of such compositions in human therapeutics, characterized by the association of a muramyl peptide with a cytokine
US5482698A (en) 1993-04-22 1996-01-09 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin polymer conjugates
DE69433519T2 (de) 1993-07-14 2004-11-11 The Regents Of The University Of California, Oakland Sich selbst zusammensetzendes polynukleotid-abgabesystem, das dendrimer-polykationen enthält
US5834441A (en) 1993-09-13 1998-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Adeno-associated viral (AAV) liposomes and methods related thereto
CN1044781C (zh) * 1994-02-05 1999-08-25 丹东市生物制品免疫技术应用研究中心 复方免疫抗生素
US5417982A (en) * 1994-02-17 1995-05-23 Modi; Pankaj Controlled release of drugs or hormones in biodegradable polymer microspheres
JP2660661B2 (ja) 1994-05-11 1997-10-08 株式会社バイオセンサー研究所 遺伝子の定量方法
JPH09503003A (ja) 1994-06-16 1997-03-25 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ クラスｉｉのアルファ鎖断片による免疫調節
US5547668A (en) 1995-05-05 1996-08-20 The Board Of Trustees Of The University Of Illinois Conjugates of folate anti-effector cell antibodies
US5753625A (en) 1995-05-12 1998-05-19 Sangstat Medical Corporation Treatment for inhibiting the progression of autoimmune disease
US5602171A (en) * 1995-06-07 1997-02-11 Sugen Inc. Methods of inhibiting phosphatase activity and treatment of disorders associated therewith using naphthopyrones and derivatives thereof
WO1997024140A1 (en) 1996-01-02 1997-07-10 The Board Of Trustees Of Leland Stanford Junior University Interaction of hla proteins with members of the hsp70 family of proteins
US6509313B1 (en) * 1996-02-28 2003-01-21 Cornell Research Foundation, Inc. Stimulation of immune response with low doses of cytokines
EP0833666B1 (en) 1996-04-10 2003-12-10 Sangstat Medical Corporation Cytomodulating conjugates of members of specific binding pairs
US6231859B1 (en) 1996-12-02 2001-05-15 Aquila Biopharmaceuticals, Inc. Saponin adjuvant compositions
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
NZ500779A (en) 1997-05-20 2001-06-29 Galenica Pharmaceuticals Inc Triterpene saponin analogs having adjuvant and immunostimulatory activity
US5891432A (en) * 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
WO1999020626A1 (en) * 1997-10-17 1999-04-29 Purdue Research Foundation Folic acid derivatives
DE19746173A1 (de) * 1997-10-18 1999-04-22 Boehringer Ingelheim Int Tumorvakzine
US6262029B1 (en) 1998-08-14 2001-07-17 Galenica Pharmaceuticals, Inc. Chemically modified saponins and the use thereof as adjuvants
AU771330B2 (en) * 1998-08-19 2004-03-18 Baxter Healthcare Sa Immunogenic beta-propionamido-linked polysaccharide protein conjugate useful as a vaccine produced using an N-acryloylated polysaccharide
WO2001032207A1 (en) * 1998-10-30 2001-05-10 United States Army Medical Research And Materiel Command Methods for conferring active/passive immunotherapy
AUPQ071299A0 (en) 1999-06-02 1999-06-24 Access Pharmaceuticals Australia Pty Limited Vitamin directed dual targeting therapy
CA2380888A1 (en) 1999-08-17 2001-02-22 Purdue Research Foundation Treatment of metastatic disease
DE60045075D1 (de) 1999-08-17 2010-11-18 Purdue Research Foundation Anti-epha2 antikörper als krebsdiagnostikum
AU7123500A (en) 1999-09-08 2001-07-09 Sloan-Kettering Institute For Cancer Research Polysialic acid-klh conjugate vaccine
EE200200158A (et) 1999-09-25 2003-06-16 University Of Iowa Research Foundation Immunostimulatoorsed nukleiinhapped
MXPA02003059A (es) 1999-09-27 2002-09-30 Univ Iowa Res Found Metodos relacionados con interferon inducido por acido nucleico inmunoestabilizador.
US20020039583A1 (en) 1999-09-30 2002-04-04 Subjeck John R. Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
JP2003527352A (ja) 2000-01-13 2003-09-16 アンティジェニクス インコーポレーテッド Ｃｐｇおよびサポニンの自然免疫刺激化合物、ならびにそれらの方法
AU5697001A (en) 2000-03-31 2001-10-15 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
ATE451935T1 (de) 2001-09-28 2010-01-15 Purdue Research Foundation Behandlungsverfahren mit liganden- immunogenkonjugaten
AR039429A1 (es) 2002-04-19 2005-02-16 Endocyte Inc Metodo para aumentar la eliminacion especifica mediada por la respuesta inmune endogena de la poblacion de celulas patogenicas en un animal huesped inmunizado previamente, composicion y combinacion que comprenden un auxiliar th1 y un conjugado hapten-portador de utilidad en el mismo.
WO2004069159A2 (en) 2003-01-27 2004-08-19 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
US20050222068A1 (en) 2003-10-23 2005-10-06 Mourich Dan V Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells
WO2007092299A2 (en) 2006-02-03 2007-08-16 Purdue Research Foundation Targeted conjugates and radiation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688488A (en) * 1989-04-03 1997-11-18 Purdue Research Foundation Composition and method for tumor imaging

Also Published As

Publication number Publication date
CN1441676B (zh) 2012-08-22
JP2003528924A (ja) 2003-09-30
MXPA02009454A (es) 2003-04-10
US20010031252A1 (en) 2001-10-18
US20060067946A1 (en) 2006-03-30
US8105608B2 (en) 2012-01-31
HRP20020787A2 (en) 2004-02-29
EA200201042A1 (ru) 2003-04-24
NZ521898A (en) 2004-11-26
IL151927A0 (en) 2003-04-10
SK13962002A3 (sk) 2004-02-03
IL213240A0 (en) 2011-07-31
EP1267918A1 (en) 2003-01-02
JP2012092097A (ja) 2012-05-17
NO332160B1 (no) 2012-07-09
WO2001074382A9 (en) 2002-10-10
CN1441676A (zh) 2003-09-10
CA2405299C (en) 2014-07-22
HUP0300421A2 (hu) 2003-06-28
KR20020087431A (ko) 2002-11-22
JP5632813B2 (ja) 2014-11-26
DZ3332A1 (fr) 2001-10-11
AU5697001A (en) 2001-10-15
PL357943A1 (en) 2004-08-09
JP5059271B2 (ja) 2012-10-24
KR100863632B1 (ko) 2008-10-15
CN102805868A (zh) 2012-12-05
SK288201B6 (sk) 2014-06-03
AU2001256970C1 (en) 2008-07-03
WO2001074382A1 (en) 2001-10-11
PL211872B1 (pl) 2012-07-31
US7033594B2 (en) 2006-04-25
AU2001256970B2 (en) 2007-06-14
CA2405299A1 (en) 2001-10-11
CZ304942B6 (cs) 2015-02-04
IL213240A (en) 2015-04-30
EA005823B1 (ru) 2005-06-30
BR0109704A (pt) 2003-04-29
EP1267918A4 (en) 2007-06-27
NO20024577L (no) 2002-11-05
NO20024577D0 (no) 2002-09-24
CZ20023240A3 (cs) 2003-10-15

Similar Documents

Publication Publication Date Title
HRP20020787B1 (en) Method of treatment using ligand-immunogen conjugates
EA200401522A1 (ru) Противотуберкулёзный препарат: композиции и способы
EE04239B1 (et) Hüdroksüülamiini derivaadid, mis on kasutatavad molekulaarse seostusvalgu moodustumise suurendamiseks, ja nende valmistamine
EA200201000A1 (ru) Гормон-заместительная терапия
UA85993C2 (ru) Конъюгат, который содержит бактериальный суперантиген и антительную составную, фармацевтическая композиция, которая его содержит, и способ лечения рака у млекопитающего
DK0740650T3 (da) Codrugs som metode til styret transport af lægemiddel
IS6750A (is) Samrunnin heterósýklísk súkkínímíð efnasambönd oghliðstæður þeirra, stillar fyrir starfsemi kjarnahormónaviðtaka
DK1187629T3 (da) Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
FI20050467A (fi) Menetelmiä kasvuhormonin vapautumisen edistämieksi eläimessä
EA199800563A1 (ru) Антагонисты гормона, высвобождающего гонадотропин
ATE332918T1 (de) Neoglycoproteine
BR9510168A (pt) Composto poliaminoácido composição forma unitária de dosagem e método par epreparar uma composição
IL206830A (en) Use of an integrin-containing antagonist of the alpha 1 subunit - of the integrin to prepare a drug for the treatment of osteoporosis
DK1053256T3 (da) Antistoffer mod Dødsreceptor 4 (DR4) og anvendelser deraf
HRP20030046B1 (en) Pharmaceutical compositions for the treatment of mucositis, stomatitis and behcet's syndrome
DK1448229T3 (da) Farmaceutisk sammensætning til at inducere et immunrespons hos et menneske eller et dyr
FI964285A (fi) Taksaanien luokkaan kuuluviin johdannaisiin perustuvat farmaseuttiset valmisteet
DE69231663T2 (de) Polysaccharid-protein-konjugate
PT1272199E (pt) Terapias de combinacao com actividade de lesao vascular
DK0969873T3 (da) Multiple carbonhydratholdige glycopeptid-antigener, vaccine indeholdende dem og anvendelse deraf
DK1207870T3 (da) Farmaceutiske præparater, der indeholder N-palmitoylethanolamid og anvendelse deraf
DK1057828T3 (da) Orale trovafloxacin-suspensioner
WO2002032378A3 (en) Fusion cells and cytokine compositions for treatment of disease
SE0003476D0 (sv) Compounds
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
RESP Petition for restitutio in integrum
RESU Restitutio in integrum adopted
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20140310

Year of fee payment: 14

PBON Lapse due to non-payment of renewal fee

Effective date: 20150330